newsfilter
← Latest News
GlobeNewswire·

NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration

NTHI
  • NeOnc Technologies signed a non-binding Memorandum of Understanding with the Department of Health – Abu Dhabi on Oct. 21, 2026, to advance research & clinical capabilities in oncology & CNS therapeutics.
  • The collaboration framework covers scientific exchange, specialist training, real-world evidence generation, & assessment of clinical trial opportunities.
  • Two children in Abu Dhabi are currently receiving investigational NEO100 via NeOnc's Compassionate Care program, with a third child expected to join from India this week.
  • The Department of Health granted Investigational New Drug status for NEO100 & NEO212 in June 2026 for adult glioma studies & pending pediatric trials, though patient enrollment requires separate Institutional Review Board approval.
  • The parties will cooperate on capacity building for investigators & healthcare professionals, including training in trial conduct, neuro-oncology imaging, & molecular diagnostics.
  • Future discussions include the potential establishment of a regional presence, manufacturing, or distribution activities for NeOnc in Abu Dhabi, subject to further agreements & regulatory approvals.
  • The MoU remains in effect for two years from the signing date unless terminated with at least three months' notice.